<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C691689D-16D2-417A-8BAD-C1A7C5070D1F"><gtr:id>C691689D-16D2-417A-8BAD-C1A7C5070D1F</gtr:id><gtr:firstName>Weng</gtr:firstName><gtr:surname>Chan</gtr:surname><gtr:orcidId>0000-0002-0488-825X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EBABB71C-FC61-4893-95D0-894123374163"><gtr:id>EBABB71C-FC61-4893-95D0-894123374163</gtr:id><gtr:firstName>Anne</gtr:firstName><gtr:otherNames>Elizabeth</gtr:otherNames><gtr:surname>Willis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0502172"><gtr:id>DB8D8A46-BC58-4591-9A08-53025B122A62</gtr:id><gtr:title>Modulation of viral Internal Ribosome Entry Segments (IRES)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502172</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-10-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>82820</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy</gtr:department><gtr:description>Dicistronic construct comprising T7 driven Renilla luciferase and HCV IRES driven firefly luciferase</gtr:description><gtr:id>1132B62D-CE82-4195-9D0A-62112DBF97BC</gtr:id><gtr:impact>As part of the aims of the Discipline Hopping award, the PI obtained hands-on training in cellular and molecular biological techniques.</gtr:impact><gtr:outcomeId>33CE25331BF-1</gtr:outcomeId><gtr:partnerContribution>Provided research training and molecular tools to screen for HCV IRES inhibitors</gtr:partnerContribution><gtr:piContribution>Design and synthesis of chemical reagents for IRES inhibition screens</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We developed a convergent approach for the chemical synthesis of tripeptide-aminoanthraquinones (AAQ) conjugates. In brief, the cationic tripeptides, constructed by solid-phase chemistry on 1,3-diaminopropane chlorotrityl resin, were released by mild acidolysis to afford the partially protected peptides . The modified peptides were then selectively conjugated with the 6-bromohexanoyl-modified AAQ. The ten tripeptides-AAQ were obtained in good yields, but were of unacceptable aqueous solubility, even in the presence of DMSO; hence, we were unable to exploit these chemical tools to modulate HCV IRES function. Three 1-phenylethyl-3-pyrimidineguanidines (PPG) analogues, accessed via a 3-step synthetic strategy, were readily obtained and purified by reversed phase-HPLC. Novel PPG-AAQ conjugates were constructed. These are: (i) 3-(4-(2-(3-(4,6-dimethylpyrimidin-2-yl)guanidino)ethyl)phenoxy)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)propanamide; and (ii) 6-(4-(2-(3-(4,6-dimethylpyrimidin-2-yl)guanidino)ethyl)phenoxy)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)hexanamide.</gtr:description><gtr:id>DD8D0FC6-4111-4095-BBE0-4FD928099090</gtr:id><gtr:impact>The impact is not obvious at the moment.</gtr:impact><gtr:outcomeId>7C55F551942</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Synthetic methods and new 1-phenylethyl-3-pyrimidineguanidines</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G0502172</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>